

**Microarray-Based Determination of Estrogen Receptor, Progesterone Receptor, and HER2 Receptor Status in Breast Cancer**

Paul Roepman,<sup>1</sup> Hugo M. Horlings,<sup>2</sup> Oscar Krijgsman,<sup>1</sup> Marleen Kok,<sup>2</sup>  
 Jolien M. Bueno-de-Mesquita,<sup>4</sup> Richard Bender,<sup>6</sup> Sabine C. Linn,<sup>3</sup>  
 Annuska M. Glas,<sup>1</sup> and Marc J. van de Vijver<sup>5</sup>

**Abstract Purpose:** The level of estrogen receptor (ER), progesterone receptor (PR), and HER2 aids in the determination of prognosis and treatment of breast cancer. Immunohistochemistry is currently the predominant method for assessment, but differences in methods and interpretation can substantially affect the accuracy, resulting in misclassification. Here, we investigated the association of microarray-based mRNA expression levels compared with immunohistochemistry.

**Experimental Design:** Microarray mRNA quantification of ER, PR, and HER2 was done by the developed TargetPrint test and compared with immunohistochemical assessment for breast tumors from 636 patients. Immunohistochemistry was done in a central laboratory and in an independent reference laboratory according to American Society of Clinical Oncology/College of American Pathologists guidelines for 100 cases. For HER2 immunohistochemistry 2+ cases, additional chromogenic *in situ* hybridization (CISH) was used to determine the final status.

**Results:** ER concordance between microarray and central immunohistochemistry was 93% [95% confidence interval (95% CI), 91-95%]. Only 4% of immunohistochemistry-positive samples were classified negative using microarray, whereas 18% of immunohistochemistry-negative samples showed a positive microarray ER status. Concordance for PR was 83% (95% CI, 80-86%) and 96% of all samples showed an identical classification of HER2 status by microarray and immunohistochemistry/CISH (95% CI, 94-98%). Nine percent of immunohistochemistry HER2-positive samples showed a negative microarray classification. Detailed review of 11 cases with discordant classifications by American Society of Clinical Oncology/College of American Pathologists and central immunohistochemistry indicated that microarray assessment was likely to add additional information in 5 cases.

**Conclusion:** Microarray-based readout of ER, PR, and HER2 shows a high concordance with immunohistochemistry/CISH and provides an additional, objective, and quantitative assessment of tumor receptor status in breast cancer. (Clin Cancer Res 2009;15(22):7003-11)

**Authors' Affiliations:** <sup>1</sup>Agendia BV; Divisions of <sup>2</sup>Experimental Therapy and <sup>3</sup>Medical Oncology and <sup>4</sup>Department of Pathology, Netherlands Cancer Institute; <sup>5</sup>Department of Pathology, Academic Medical Centre, Amsterdam, The Netherlands and <sup>6</sup>Agendia, Inc., Huntington Beach, California  
 Received 2/24/09; revised 8/19/09; accepted 8/19/09; published OnlineFirst 11/3/09.

**Grant support:** Top Institute Pharma project T3-108.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked *advertisement* in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

**Requests for reprints:** Marc J. van de Vijver, Academic Medical Centre, Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands. Phone: 31-20-566-4100; Fax: 31-20-566-9523; E-mail: m.j.vandevijver@amc.uva.nl and Annuska M. Glas, Agendia BV, Science Park 406, 1098 XH Amsterdam, The Netherlands. Phone: 31-20-462-1500; Fax: 31-20-462-1505; E-mail: annuska.glas@agendia.com.

© 2009 American Association for Cancer Research.  
 doi:10.1158/1078-0432.CCR-09-0449

Breast cancer is the most common malignancy in women. The level of estrogen receptor (ER) and progesterone receptor (PR) is prognostic in early-stage breast cancer patients and predictive for response to tamoxifen and other hormonal therapies (1-4). HER2 overexpression and/or amplification is an additional prognostic molecular marker (5) indicated for selection of patients for trastuzumab or other HER2-targeted therapies (6, 7). Accordingly, primary breast carcinomas should be tested for these three molecular markers for optimal diagnosis and treatment selection for the patient.

Immunohistochemistry is currently the predominant method for determination of ER, PR, and HER2 status (8), often with additional *in situ* hybridization assays to clarify HER2 immunohistochemical results (9). Despite its long-term use, immunohistochemical assays have not been standardized

### Translational Relevance

In this study, we have examined the association of the expression of the estrogen receptor (ER), progesterone receptor (PR), and HER2 genes as measured by microarray analysis with the expression of the proteins encoded by these genes as determined by immunohistochemistry. We show that there is a very high correlation between the expression of these genes at the mRNA level and the expression of the proteins as quantified by immunohistochemistry. These findings are relevant to clinical practice, as determination of ER, PR, and HER2 plays a very important role in guiding systemic therapy in individual breast cancer patients. Because it is known that there is marked variability in the outcome of the determination of ER, PR, and HER2 among pathology laboratories, with relatively high false-positive and false-negative testing rates, microarray-based assessment of these genes could be used for the determination of ER, PR, and HER2 status.

and differences in tissue fixation, choice of antibody, scoring method, and interpretation can significantly affect the accuracy and reproducibility of hormone receptor and HER2 testing (10–12). Several studies have indicated a high degree of interobserver and interlaboratory variation (13–16). False-negative rates for hormone receptor status typically range between 20% and 30% (17), with some studies reporting a false-negative rate up to 60% to 70% (18, 19). HER2 false-positive rates can range from 20% to 30% for immunohistochemistry and 10% to 15% for fluorescence *in situ* hybridization (FISH) analysis (20, 21). Although guidelines have been defined for immunohistochemical assessment of HER2 (22), possibly decreasing the number of misclassifications, more accurate and reproducible tests would optimize the selection of patients for hormone receptor and HER2-targeted treatment.

Microarrays have been shown to be valuable for molecular classification of breast tumors (23) and for accurate assessment of prognosis (24, 25) and treatment response (26, 27) of breast cancer patients. In this study, we investigated the value of standardized microarray gene expression readout as an objective alternative to immunohistochemistry and FISH. We compared microarray measurements of ER, PR, and HER2 to multiple immunohistochemical determinations for breast tumors from 636 patients and investigated the potential benefit of microarray assessment in addition to standard immunohistochemistry/chromogenic *in situ* hybridization (CISH).

### Materials and Methods

**Tumor samples.** Previously determined microarray gene expression measurements of ER, PR, and HER2 in 295 breast cancer samples (24) were used for training and primary validation of microarray readout (cohort 1, Table 1). One hundred samples were randomly assigned as training samples and the remaining 195 samples were used for validation. Two additional cohorts (cohorts 2 and 3, Table 1) were selected for validation of microarray readout. Cohort 2 consisted of early-stage breast cancer samples from 241 patients and cohort 3 ( $n = 100$ ) was selected from patients within the RASTER study (28) to include

approximately two-thirds hormone-positive samples and one-third HER2-positive samples. For all cohorts, tumor samples were assessed histologically to confirm invasive ductal carcinoma or invasive lobular carcinoma and the presence of sufficient tumor cells. Of the 636 samples that were used for this study, we could successfully determine ER/PR and HER2 status using both immunohistochemistry and microarray for 575 and 567 samples, respectively.

**Immunohistochemistry and CISH/FISH.** For all specimens, ER, PR, and HER2 status were assessed by analyzing the expression of these proteins using immunohistochemistry. Tissue microarrays were constructed from paraffin blocks with breast tumor samples that belong to patient cohorts 1 and 2 by a manual tissue arrayer (Beecher Instruments). Core tissue biopsies of 600  $\mu\text{m}$  cores were taken from each individual paraffin-embedded tumor and arrayed in triplicate in a new paraffin block. Serial sections of 3  $\mu\text{m}$  were cut from the tissue microarray blocks, deparaffinized in xylene, and hydrated in a graded series of alcohol. Immunohistochemistry of all samples was centrally performed by the pathology laboratory of the Netherlands Cancer Institute using the Lab Vision Immunohistochemical Autostainer with primary antibodies against ER- $\alpha$  (1D5 + 6F11, dilution 1:50; Neomarkers, Lab Vision), PR (R-1, dilution 1:500; Clinipath), and HER2 (cohorts 1 and 2: antibody 3B5, dilution 1:3,000; cohorts 2 and 3: antibody SP3, dilution 1:25; ref. 29). Immunohistochemical analysis of ER, PR, and HER2 for cohort 3 was done on individual paraffin-embedded tumor slides at the originating hospital according to local standards (28), at a central laboratory (Netherlands Cancer Institute), and at an independent College of American Pathologists (CAP)-accredited U.S. reference laboratory using Food and Drug Administration-approved procedures and American Society of Clinical Oncology (ASCO)/CAP guidelines (Table 1).

Central laboratory scoring of the immunohistochemical staining was done by an experienced pathologist (M.J.V.). ER and PR were determined based on the percentage of tumor cells showing positive nuclear staining and were considered positive if nuclear staining was present in  $\geq 10\%$  of the cells according to Dutch guidelines.<sup>7</sup> HER2 expression was scored as follows: 0 for no staining at all or membrane staining in  $< 10\%$  of the tumor cells, 1+ for a faint/barely perceptible partial membrane staining in  $\geq 10\%$  of the tumor cells, 2+ for weak to moderate complete membrane staining in  $\geq 10\%$  of the tumor cells, and 3+ for strong complete membrane staining in  $\geq 10\%$ . HER2 was considered positive if the score was 3+. HER2 status was evaluated according to commonly accepted pathologic guidelines (30). A tumor was considered to be HER2-positive when a score of 3+ was found and negative when a score of 0 or 1+ was observed. Tumors with a score of 2+ were evaluated by CISH; tumors with HER2 gene amplification ( $\geq 6$  spots per tumor cells) were scored as HER2-positive and all other tumors as HER2-negative.

ASCO/CAP reference scoring was done consistent with good clinical practice guidelines in a good laboratory practice-approved laboratory. Receptor testing was done using Ventana ultraView Universal DAB kit (Ventana Medical Systems), Vision Biosystems (Novocastra) antibodies for ER (clone 6F11) and PR (clone 16), and DAKO Herceptest for HER2, all of which are Food and Drug Administration cleared for *in vitro* diagnostic use. ER and PR results are reported as positive or negative, and % positive in 10% increments and stain intensity are given. Any positive staining of tumor nuclei is considered a positive result, but cases with minimal staining are reported as  $\leq 5\%$  staining. HER2 immunohistochemistry is reported as 0, 1, 2, 3+ according to CAP guidelines (membrane staining only). Samples with a score of 2+ were evaluated by FISH and reported as positive for *HER2/CEP17*  $> 1.80$ .

For 536 of the 636 samples reported in this study central immunohistochemistry was done using tissue microarray (cohort 1,  $n = 295$  and cohort 2,  $n = 241$ ). ER and PR status could successfully be assessed by tissue microarray immunohistochemistry for 89% of the samples and HER2 immunohistochemistry/CISH could successfully be performed for 88% of all tissue microarray cases (Table 1). The 100 samples within

<sup>7</sup> www.oncoline.nl

**Table 1.** Overview of sample sets used for development of ER, PR, and HER2 readout by immunohistochemistry (local, central, and ASCO/CAP) and TargetPrint microarrays

Total			Cohort 1 295	Cohort 2 241	Cohort 3 100	Total 636
ER	Immunohistochemistry	Tissue	Tissue microarray	Tissue microarray	Whole sections	
		Local	-	-	100	100
		Central	286	193	96	575
	TargetPrint	ASCO/CAP	-	-	87	87
		Train	295	241	100	636
		Validation	100	-	-	100
PR	Immunohistochemistry	Local	-	-	100	100
		Central	286	193	96	575
		ASCO/CAP	-	-	87	87
	TargetPrint	Train	295	241	100	636
		Validation	100	-	-	100
		Validation	186	193	96	475
HER2	Immunohistochemistry/CISH	Local	-	-	82	82
		Central	273	198	96	567
		ASCO/CAP	-	-	85	85
	TargetPrint	Train	295	241	100	636
		Validation	100	-	-	100
		Validation	173	198	96	467

NOTE: "Immunohistochemistry tissue" indicates the type of tissue that was used for immunohistochemical assessment: tissue microarrays or whole sections.

cohort 3 were selected based on a successful local immunohistochemical assessment (and selected to include approximately two-thirds hormone-positive samples and one-third HER2-positive samples) and were subsequently scored for immunohistochemistry by a central and an ASCO/CAP laboratory using whole sections instead of tissue microarray. Success rates of central and CAP immunohistochemistry were 96% and 87% for ER/PR scoring and 96% and 85% for HER2 assessment, respectively. The main cause of failure of central and CAP immunohistochemistry was the unavailability of paraffin-embedded tumor tissue with sufficient tumor cells, as these samples had been used extensively for other studies.


**Microarray readout of ER, PR, and HER2 by TargetPrint.** TargetPrint microarrays (Agendia) contain multiple replicate probes for detection of mRNA levels of ER (*ESR1*; 9 probes), PR (*PGR*; 9 probes), and HER2 (*ERBB2*; 6 probes) and a large number of probes for normalization (465) and quality-control (536) purposes. RNA isolation, labeling and hybridization were done as described previously (31). To ensure sufficient tumor volume for microarray analysis, all samples included in this study showed a tumor cell percentage of at least 50%. Tumor samples were between 3 and 6 mm in diameter and ~30 sections of 30  $\mu\text{m}$  were used for RNA isolation, making a total of 3 to 6  $\text{mm}^2$  tumor volume for microarray readout. Fluorescence intensities on scanned images were quantified and normalized using Feature Extraction software (Agilent Technologies). To obtain an accurate measurement of ER, PR, and HER2 mRNA levels, an error-weighted mean value was calculated for multiple replicate probes of each receptor (32). Appropriate relative weights for each of the replicate probes were established by the Rosetta error model, which corrects for the uncertainties in individual probe measurements and combines the replicate probe measurement in a single score for each of the measured receptors (32). Measurement scores of ER, PR, and HER2 across a cohort of 100 training samples were correlated with immunohistochemical determination and the optimal microarray threshold determined (using a 10-fold cross-validation) with highest concordance to immunohistochemistry. Tumor samples with a microarray score  $\geq 0$  were considered positive for ER, PR, and HER2. Microarray readout was validated against immunohistochemistry on >450 additional samples.

**Statistical analysis.** Statistical analysis was done in R/Bioconductor. Correlation of continuous microarray readout with immunohistochemical assessment was determined using Pearson correlation and linear fit models. Agreement measurements between binary microarray and immunohistochemical classifications were based on two-way contingency table analysis and included overall concordance, positive agreement defined as the number of samples classified positive by both immunohistochemistry and microarray divided by the number of positive samples using immunohistochemistry, negative agreement, and Cohen's  $\kappa$  coefficient scores (33). All measurements were associated with 95% confidence intervals (95% CI). Statistical tests were considered significant for  $P < 0.05$ .

## Results

ER, PR, and HER2 microarray readout of 100 training samples selected from cohort 1 were compared with central immunohistochemical determination. Optimal microarray thresholds for ER, PR, and HER2 with the lowest discordance to immunohistochemistry/CISH were determined and classified 76% and 63% of the samples as ER-positive and PR-positive, respectively, and 22% as HER2-positive (Fig. 1). Compared with immunohistochemistry, microarray readout showed a concordance of 88% (95% CI, 81-92%) for ER, 85% (95% CI, 77-91%) for PR, and 95% (95% CI, 89-97%) for HER2.

Microarray readout was validated on the remaining samples within cohort 1 and cohorts 2 and 3 for which the corresponding receptor status could successfully be determined by immunohistochemistry/CISH as well as by microarray ( $n = 475$  for ER and PR and  $n = 467$  for HER2; Table 1). Microarray measurements correlated strongly with central immunohistochemical determination (ER:  $r = 0.77$ ,  $P < 0.0001$ , Fig. 2A; PR:  $r = 0.61$ ,  $P < 0.0001$ , Fig. 2B; and HER2:  $r = 0.76$ ,  $P < 0.0001$ , Fig. 2C) with a significant difference in readout between immunohistochemistry-negative and immunohistochemistry-positive




**Fig. 1.** Microarray gene expression scores of ER (A), PR (B), and HER2 receptor (C) can accurately distinguish immunohistochemistry-positive (+CISH) and immunohistochemistry-negative tumor samples ( $n = 100$ , training cohort). Vertical dashed lines represent microarray thresholds for ER, PR, and HER2.

samples (ER:  $-0.232$  versus  $0.414$ ,  $P < 0.0001$ ; PR:  $-0.084$  versus  $0.314$ ,  $P < 0.0001$ ; and HER2:  $-0.372$  versus  $0.473$ ,  $P < 0.0001$ ). Thus, 79%, 64%, and 22% of the validation samples were classified positive for ER, PR, and HER2 by microarray, respectively.

Concordance between microarray readout by TargetPrint and central immunohistochemistry was high (Table 2). ER assessment showed a concordance of 93%, with a  $\kappa$  score of 0.79 (95% CI, 0.72-0.85). Positive agreement was 95% (95% CI, 94-96%) and negative agreement was 85% (95% CI, 80-90%). Only 15 of 373 (4%) samples that were scored ER-positive by immunohistochemistry were negative using microarray, whereas, interestingly, 18 of 102 (18%) samples classified negative by immunohistochemistry showed a positive microarray ER status. PR assessment showed a concordance of 83% (95% CI, 80-86%) with a  $\kappa$  score of 0.65 (95% CI, 0.58-0.71; Table 2). About one-quarter (26%) of immunohistochemistry PR-negative samples showed positive microarray readout. Concordance between microarray and immunohistochemistry for HER2 was very high (96%; 95% CI, 94-98%) with

a  $\kappa$  of 0.88 (Table 2), a positive agreement of 90% (95% CI, 84-93%), and an agreement for HER2-negative cases of 98% (95% CI, 97-99%). Three percent of the samples classified as HER2-negative by immunohistochemistry were scored positive by microarray readout. On the other hand, 9% of samples that were classified positive for HER2 by immunohistochemistry had a negative readout by microarray. Interestingly, within HER2 immunohistochemistry 2+ cases, microarray identified HER2 CISH-positive and HER2 CISH-negative samples in a high proportion of cases (accuracy of 87%,  $\kappa = 0.72$ ; Supplementary Data 1).

Next, we compared the ER, PR, and HER2 status of cohort 3 samples (Table 1) that were classified in duplicate by TargetPrint microarrays and in triplicate by immunohistochemistry according to local, central, and ASCO/CAP standards. Samples were preselected for a relatively high concordance between local and central immunohistochemistry (>90% for ER and HER2). Duplicate microarray analysis showed a very high concordance (Table 3). Comparison of microarray results with immunohistochemistry (including CISH for HER2) performed according to



**Fig. 2.** Validation of microarray readout of ER (A), PR (B), and HER2 receptor (C) versus immunohistochemical assessment. The microarray score on the Y axis shows log mRNA expression levels. The central immunohistochemistry on the X axis shows ER and PR levels ( $n = 475$ ) as percentage positively stained tumor cells. HER2 expression ( $n = 467$ ) was scored as 0, 1+, 2+/CISH-negative, 2+/CISH-positive, or 3+. Thresholds for positive sample scoring are indicated by the horizontal and vertical dashed lines, respectively.

the three different standards indicated similar concordances of 92%, 93%, and 92% for ER; 84%, 81%, and 86% for PR; and 93%, 95%, and 94% for HER2 (Table 3). Discordance between microarray and ASCO/CAP immunohistochemistry was very low for ER (8%) and HER2 (6%) and low for PR (14%) and was comparable with the misclassification rate among the three immunohistochemical laboratories (local, central, and ASCO/CAP).

ASCO/CAP reference immunohistochemistry used a threshold of 1% positive tumor cells compared with the 10% threshold for positive staining on which the TargetPrint readout was developed. However, none of the observed discordance in cohort 3 was due to the use of different criteria for immunohistochemical determination, as none of the samples scored by ASCO/CAP showed a staining between 1% and 10%.

We further investigated if the discordance between microarray and central immunohistochemistry of all analyzed samples in cohorts 1, 2, and 3 could be explained by the difference in the cutoff for positive versus negative (1% and 10% positivity). The 18 ER discordant samples that were classified positive by microarray readout but negative by immunohistochemistry using a

cutoff of 10% (18 of 376 samples) were all scored by immunohistochemistry as 0%. Therefore, this discordance could not be explained by a difference in ER immunohistochemical threshold. Of the 53 samples that were scored positive for PR by microarray but negative by immunohistochemistry >10%, 10 samples showed staining between 1% and 5% and could be reported positive for immunohistochemistry with a threshold of 1%, thereby lowering the false-positive rate for PR from 18% to 14%.

Finally, we checked whether the discordance rate between immunohistochemistry and microarray could partially be explained by the differences in immunohistochemical determination using tissue microarrays (cohorts 1 and 2) versus using whole sections for antibody staining (cohort 3). Concordance rates of tissue microarray versus microarray and whole sections versus microarray were high with 0.93 (353/379) and 0.95 (91/96) for ER classification and 0.84 (318/379) and 0.80 (77/96) for PR classification, respectively, indicating that use of tissue microarray or whole sections had no effect on the observed discordance.

To take a closer look at the discrepancies between microarray readout and immunohistochemistry and to investigate which

**Table 2.** Contingency table of microarray readout by microarray and central immunohistochemistry of ER, PR, and HER2 on all validation samples

	Central immunohistochemistry +	Central immunohistochemistry -	Total		(95% CI)
ER					
Microarray +	358	18	376	Concordance	93% 91-95%
Microarray -	15	84	99	$\kappa$	0.79 0.72-0.85
PR					
Microarray +	247	53	300	Concordance	83% 80-86%
Microarray -	26	149	175	$\kappa$	0.65 0.58-0.71
HER2					
Microarray +	85	10	95	Concordance	96% 94-98%
Microarray -	8	364	372	$\kappa$	0.88 0.81-0.92

**Table 3.** Concordance between immunohistochemical assessment at local, central, and ASCO/CAP reference laboratory immunohistochemical assessment and microarray readout of 100 breast tumor samples (cohort 3)

	<i>n</i>	ER		PR		HER2	
		Concordance	$\kappa$	Concordance	$\kappa$	Concordance	$\kappa$
Local vs central immunohistochemistry	96	0.94	0.86	0.89	0.77	0.96	0.87
Local vs reference immunohistochemistry	87	0.99	0.97	0.90	0.79	0.94	0.88
Local immunohistochemistry vs microarray	100	0.92	0.82	0.84	0.67	0.93	0.85
Central vs reference immunohistochemistry	84	0.94	0.87	0.94	0.88	0.95	0.89
Central immunohistochemistry vs microarray	96	0.93	0.82	0.81	0.61	0.95	0.89
Reference immunohistochemistry vs microarray	87	0.92	0.82	0.86	0.72	0.94	0.87
Microarray vs microarray	88	1.00	1.00	0.97	0.93	1.00	0.98

method gave more reproducible results, we performed a detailed second review of several discordant samples between TargetPrint and central immunohistochemistry. For this analysis, we restricted ourselves to discordance within cohort 3 as immunohistochemistry for this cohort was based on complete tumor slides (tissue microarray were used for cohorts 1 and 2) and because these samples were also assessed by an independent ASCO/CAP-certified reference laboratory. Sample review was based on three additional determinations of ER and HER2: a new readout by TargetPrint microarray, an assessment by the ASCO/CAP reference laboratory using new tissue sections, and also by a blindly performed rescoring of the centrally performed immunohistochemistry, which, if the result of the rescoring remained discordant, was restained and again rescored blindly. Eleven discordant cases were analyzed, 6 with mismatching ER and 5 with mismatching HER2 readouts (Table 4).

Reassessment of all selected samples by microarray indicated a similar result for all samples and suggested reliable detection of ER and HER2 RNA levels within the tumor samples. Review of the six ER discordant cases based on ASCO/CAP and central immunohistochemistry indicated that, for two samples (#26 and #30), the original immunohistochemical determination

was likely inaccurate as immunohistochemical review of both indicated a different outcome (although sample #26 remained borderline ER-positive). Secondary review of one sample (#92) showed no clear result as the ER remained around the borderline (0%, 5%, and 10%). For the remaining three samples (#57, #74, and #92), immunohistochemistry and microarray remained discordant. Of the five selected HER2 discordant cases, three samples (#48, #62, and #94) remained discordant between microarray and immunohistochemistry/FISH. Interestingly, although sample #94 remained discordant after review, it showed borderline microarray negativity (-0.07 and -0.03) and borderline central immunohistochemistry positivity (immunohistochemistry 2+, CISH-positive). HER2 review of samples #27 and #30 indicated that the original assessment (HER2-negative) might have generated false-negative results. However, for these samples, either the microarray readout (sample #30) or the immunohistochemistry/FISH assessment (sample #27) remained questionable. Although the number of samples used for the detailed review was limited, this analysis indicates that microarray readout provides additional information regarding ER and HER2 status in about one-half (5 of 11) of the discordant cases. Interestingly, it also suggests that microarray as well as

**Table 4.** Review of 11 discordant cases with mismatching ER or HER2 microarray and central immunohistochemistry readout by additional microarray readout (review 1), by independent CAP immunohistochemistry/FISH assessment (review 2), and by restaining and/or rescoring of centrally performed immunohistochemistry (review 3)

Sample	Original			Review 1 Microarray	Review 2		Review 3	
	Central immunohistochemistry	Central CISH	Microarray		CAP immunohistochemistry	CAP FISH	Central immunohistochemistry	Central CISH
#26 ER	<b>60%</b>		-0.23	-0.24	10%		10%	
#30 ER	0%		<b>0.62</b>	<b>0.60</b>	<b>90%</b>		<b>100%</b>	
#57 ER	0%		<b>0.22</b>	<b>0.25</b>	ND		0%	
#62 ER	<b>100%</b>		-0.47	-0.44	<b>90%</b>		<b>100%</b>	
#74 ER	<b>50%</b>		-0.41	-0.41	<b>90%</b>		<b>100%</b>	
#92 ER	<b>10%</b>		-0.20	-0.20	0%		5%	
#27 HER2	1+		<b>0.46</b>	<b>0.46</b>	<b>2+</b>	<b>Positive</b>	2+	Negative
#30 HER2	0		<b>0.08</b>	<b>0.04</b>	<b>3+</b>	<b>Positive</b>	<b>2+</b>	<b>Borderline</b>
#48 HER2	<b>2+</b>	<b>Positive</b>	-0.12	-0.19	<b>3+</b>		<b>3+</b>	<b>Positive</b>
#62 HER2	0		<b>0.53</b>	<b>0.57</b>	0		0	
#94 HER2	<b>2+</b>	<b>Positive</b>	-0.07	-0.03	<b>3+</b>		2+	<b>Positive</b>

NOTE: Assessments resulting in a positive receptor status are shown in bold.

immunohistochemistry-based determinations might be correct for discordant cases, as both techniques generally result in reproducible outcomes.

## Discussion

In this study, we investigated the use of microarray-based readout of three biomarkers that are crucial for treatment decisions in breast cancer, that is, ER, PR, and HER2 (1, 2, 5, 7). Currently, immunohistochemistry is the standard for determination of ER, PR, and HER2 status (34). However, despite the long practice of immunohistochemistry, procedural inconsistency remains high in clinical settings, leading to intralaboratory and interlaboratory variation and to high false-negative (for ER and PR) and false-positive (for HER2) classifications (18, 19). Although the ASCO/CAP guidelines for HER2 assessment have recently been published (22) and those for ER/PR testing are in development,<sup>8</sup> the inconsistency in immunohistochemical determination recommends an additional, reliable, testing method to assess hormone and HER2 receptor status.

Here, we present another method for determination of ER, PR, and HER2 levels in breast cancer that is based on microarray analysis. Microarray-based readout shows a high concordance with multiple immunohistochemistry as well as CISH/FISH assessments, performed according to ASCO/CAP standards, and is based on controlled and objective quantification of receptor mRNA levels. TargetPrint microarray analysis is performed centrally in a highly qualified and Clinical Laboratory Improvement Amendments–certified microarray laboratory (31) and uses fresh (stored in a RNA-stabilizing solution) or frozen tumor tissue from which high-quality RNA can be obtained. The microarray assay has been proven to give reliable quantification of ER, PR, and HER2 levels for samples with sufficient ( $\geq 50\%$ ) tumor cells.

The high level of concordance between microarray readout and immunohistochemistry/CISH reported here (93% for ER and 96% for HER2) indicates that microarray-based readout is a reliable addition to current techniques. Our findings are in agreement with a study by Gong and colleagues, who investigated the use of Affymetrix microarrays for quantification of ESR1 and ERBB2 mRNA levels and reported an overlap of 92% with ER immunohistochemical measurement and 90% with HER2 immunohistochemistry/CISH assessment (35). Interestingly, a recent study by Badve and colleagues reported a similar lower concordance between PR mRNA levels and immunohistochemistry (36) as observed in our study. As their study used quantitative reverse transcription-PCR for PR detection instead of microarray, the lower PR concordance might not be caused by technical difficulties in one technique (e.g., low sensitivity) but could reflect real differences between RNA and protein levels. The possible occurrence of a tumor subgroup that does not express protein despite the presence of mRNA transcripts is supported by our finding that, for ER and PR, we observed a higher proportion of cases that were immunohistochemistry-positive/microarray-positive (18% and 26%) than immunohistochemistry-positive/microarray-negative (4% and 9%).

In this study, a tumor sample was classified positive by immunohistochemistry for ER and PR when at least 10% of tumor cells showed positive staining. Consensus regarding the accurate cutoff for ER and PR positivity is considered to be the  $\geq 10\%$  threshold (37). However, Harvey and colleagues reported good outcomes after adjuvant tamoxifen treatment for tumors when a lower number of cells stained positive (8). Additional support for the use of a 1% cutoff was provided by the study of Viale and colleagues who indicated a better prognosis using this threshold and some degree of endocrine responsiveness for lower staining tumors (18). We have investigated whether TargetPrint readout also validates using a cutoff of 1% and found no difference in performance for ER when a 1% threshold was used instead of a 10% threshold and a minor increase (+4%) in performance of PR using a 1% threshold for immunohistochemistry positivity. Although ER/PR-positive cases present on the same tissue microarray can be considered as positive controls, a limitation of the immunohistochemical assessment of ER and PR in this study is that we did not separately record ER and PR staining in normal epithelial cells of adjacent breast tissue in cases where the breast carcinoma was ER-negative and/or PR-negative.

Currently, there remains a controversy about the relationship of measured ER/PR immunohistochemical levels and the ER/PR protein present in the tumor cells. Whereas older ligand-binding assays indicate a continuum of values, formalin-fixed, paraffin-embedded–based immunohistochemistry generally shows a bimodal distribution instead of a broad range of values among ER-positive patients (38). In line with this controversy, the immunohistochemical methods reported in this study classified the great majority of breast tumor samples with either 0% or 100% ER positivity. Interestingly, mRNA levels measured by microarray (this study and ref. 35) or by quantitative PCR (36) show a large dynamic range within the immunohistochemistry 0% and 100% groups. The same holds true for HER2 determination in which immunohistochemistry 0 and immunohistochemistry 3+ samples show a range of HER2 gene expression levels. These observations indicate a continuum of mRNA levels of ER, PR, and HER2 within positively and negatively stained samples by immunohistochemistry. Such quantitative mRNA-based measurement, in addition to the immunohistochemical assessment, may provide clinically important prognostic and predictive information.

An important issue in studies comparing different methods for the assessment of ER, PR, and HER2 is the gold standard to which the test results are compared. The ER, PR, and HER2 status is mainly assessed to predict tumor responsiveness to hormonal therapy and to anti-HER2 therapy; however, responsiveness to these treatments can only be clinically evaluated in neoadjuvant treatment or treatment of metastatic disease. For the patients in our study (and in most other comparable studies), information on treatment response is not available. We can therefore only speculate on what the most likely “true” ER, PR, and HER2 status is for cases where there is a discrepancy between the microarray test result and immunohistochemistry (for HER2 combined with CISH/FISH).

An additional potential complication of these comparisons is that both immunohistochemistry and microarray rely on the presence of protein or mRNA, but neither assay determines whether that protein or mRNA is capable of making functional receptor proteins. As such, both methods have an inherent

<sup>8</sup> R. Bender, personal communication.

uncertainty in predicting whether a tumor is truly positive for functional ER, PR, or HER2 protein. Efforts have been made to circumvent this problem by developing assays to measure ER functionality (39). The development of additional gene signatures that reflect ER/PR positivity (40, 41) may provide another method to test for ER functionality in tumor cells. It may also be worthwhile to ask if such target gene signatures for ER as well as for HER2 are concordant with immunohistochemistry and microarray readout of ER and HER2 activity in breast cancer.

It appears that an important benefit of microarray readout will be to further develop methods to reduce false-positive and false-negative results. In this study, only 4% of all immunohistochemistry ER-positive samples were classified negative by microarray of which about one-half showed <50% positively stained cells. In contrast, 18% of immunohistochemistry ER-negative samples were classified positive by microarray. For PR, this number increases to about one in every four immunohistochemistry-negative samples. This relatively large group of immunohistochemistry classified ER/PR-negative patients might potentially benefit from hormone-targeted therapies. For HER2, very few (3%) of the samples that were classified negative by immunohistochemistry showed a positive microarray readout. However, ~10% of the immunohistochemistry/CISH HER2-positive samples were negative by microarray readout. This group of samples might represent patients that are proven immunohistochemistry HER2-positive but who may not respond to HER2-targeted therapies such as trastuzumab (42). A detailed review of discordant cases suggests a real difference between mRNA expression and measured protein levels for the majority of these particular tumor specimens in which multiple immunohistochemical assessments remained discordant with duplicate microarray readouts. Conclusions as to which method gives the most valuable readout with respect to patient outcome and treatment response remain to be determined in future studies that include treatment response information for hormone receptor-based treatment (e.g., tamoxifen and ER/PR status) and HER2-targeted therapy (e.g., trastuzumab).

We suspect that the principal clinical benefit of microarray readout will be to resolve the discordance between current methods for HER2 (e.g., CISH versus immunohistochemistry), to reduce the number of false-negative classifications for hormone receptor status and false-positive readouts of HER2 status, and to further evaluate tumors that are classified as ER-negative/PR-positive, tumors classified as ER-positive/PR-negative, and tumors classified as triple-negative (ER, PR, and HER2 negative). The developed microarray-based readout of ER, PR, and HER2 provides an objective and quantitative assessment of tumor receptor status in breast cancer. Use of microarray receptor readout in addition to current techniques may improve molecular classification of breast cancer and provide an additional rationale for hormonal and HER2-targeted therapies and clinical trial design. The MINDACT trial currently under way at >70 centers across Europe may help to answer some of these questions as both immunohistochemistry and microarray data on ER, PR, and HER2 are being obtained prospectively and correlated with the results of adjuvant endocrine therapy in over one-half of the 6,000 patients being enrolled. These results will go a long way to helping establish whether immunohistochemistry or microarray expression results correlate better with treatment outcomes.

### Disclosure of Potential Conflicts of Interest

P. Roepman, O. Krijgsman, R. Bender, and A.M. Glas are employees of Agendia.

### Acknowledgments

We thank Renske Fles, Hans Halfwerk, Petra Kristel, and Abderrahim Ajouaou for help with sample processing; Mireille Snel, Maurice Pater, and Arno Floore for microarray analysis; Rutger Koornstra for collection of clinical data; Diederik Wehkamp and Tako Bruinsma for bioinformatic and IT support; and Femke de Snoo, Okke-Jaap Bosgra, Laura van't Veer, Rene Bernards, and Giuseppe Viale for fruitful discussions and helpful suggestions.

### References

- Rose C, Thorpe SM, Løber J, Daenfeldt JL, Palshof T, Mouridsen HT. Therapeutic effect of tamoxifen related to estrogen receptor level. *Recent Results Cancer Res* 1980;71:134-41.
- Stierer M, Rosen H, Weber R, Hanak H, Spona J, Tüchler H. Immunohistochemical and biochemical measurement of estrogen and progesterone receptors in primary breast cancer. Correlation of histopathology and prognostic factors. *Ann Surg* 1993;218:13-21.
- Sunderland MC, Osborne CK. Tamoxifen in premenopausal patients with metastatic breast cancer: a review. *J Clin Oncol* 1991;9:1283-97.
- Fisher B, Redmond C, Brown A, et al. Influence of tumor estrogen and progesterone receptor levels on the response to tamoxifen and chemotherapy in primary breast cancer. *J Clin Oncol* 1983;1:227-41.
- Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. *Science* 1987;235:177-82.
- Marty M, Cognetti F, Maraninchi D, et al. Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group. *J Clin Oncol* 2005;23:4265-74.
- Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. *N Engl J Med* 2005;353:1659-72.
- Harvey JM, Clark GM, Osborne CK, Allred DC. Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. *J Clin Oncol* 1999;17:1474-81.
- Press MF, Slamon DJ, Flom KJ, Park J, Zhou JY, Bernstein L. Evaluation of HER-2/neu gene amplification and overexpression: comparison of frequently used assay methods in a molecularly characterized cohort of breast cancer specimens. *J Clin Oncol* 2002;20:3095-105.
- Hede K. Breast cancer testing scandal shines spotlight on black box of clinical laboratory testing. *J Natl Cancer Inst* 2008;100:836-7.
- Oyama T, Ishikawa Y, Hayashi M, Arihiro K, Horiguchi J. The effects of fixation, processing and evaluation criteria on immunohistochemical detection of hormone receptors in breast cancer. *Breast Cancer* 2007;14:182-8.
- Ross JS, Symmans WF, Pusztai L, Hortobagyi GN. Standardizing slide-based assays in breast cancer: hormone receptors, HER2, and sentinel lymph nodes. *Clin Cancer Res* 2007;13:2831-5.
- Kirkegaard T, Edwards J, Tovey S, et al. Observer variation in immunohistochemical analysis of protein expression, time for a change? *Histopathology* 2006;48:787-94.
- Diaz LK, Sahin A, Sneige N. Interobserver agreement for estrogen receptor immunohistochemical analysis in breast cancer: a comparison of manual and computer-assisted scoring methods. *Ann Diagn Pathol* 2004;8:23-7.
- Arihiro K, Umemura S, Kurosumi M, et al. Comparison of evaluations for hormone receptors in breast carcinoma using two manual and three automated immunohistochemical assays. *Am J Clin Pathol* 2007;127:356-65.
- Gancberg D, Järvinen T, di Leo A, et al. Evaluation of HER-2/neu protein expression in breast cancer by immunohistochemistry: an interlaboratory study assessing the reproducibility of HER-2/neu testing. *Breast Cancer Res Treat* 2002;74:113-20.
- Allred DC. Commentary: hormone receptor testing in breast cancer: a distress signal from Canada. *Oncologist* 2008;13:1134-6.

18. Viale G, Regan MM, Maiorano E, et al. Prognostic and predictive value of centrally reviewed expression of estrogen and progesterone receptors in a randomized trial comparing letrozole and tamoxifen adjuvant therapy for postmenopausal early breast cancer: BIG 1-98. *J Clin Oncol* 2007;25:3846-52.
19. Rhodes A, Jasani B, Barnes DM, Bobrow LG, Miller KD. Reliability of immunohistochemical demonstration of oestrogen receptors in routine practice: interlaboratory variance in the sensitivity of detection and evaluation of scoring systems. *J Clin Pathol* 2000;53:125-30.
20. Perez EA, Suman VJ, Davidson NE, et al. HER2 testing by local, central, and reference laboratories in specimens from the North Central Cancer Treatment Group N9831 intergroup adjuvant trial. *J Clin Oncol* 2006;24:3032-8.
21. Reddy JC, Reimann JD, Anderson SM, Klein PM. Concordance between central and local laboratory HER2 testing from a community-based clinical study. *Clin Breast Cancer* 2006;7:153-7.
22. Wolff AC, Hammond ME, Schwartz JN, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. *J Clin Oncol* 2007;25:118-45.
23. Sørlie T, Perou CM, Tibshirani R, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. *Proc Natl Acad Sci U S A* 2001;98:10869-74.
24. van de Vijver MJ, He YD, van't Veer LJ, et al. A gene-expression signature as a predictor of survival in breast cancer. *N Engl J Med* 2002;347:1999-2009.
25. Paik S, Shak S, Tang G, et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. *N Engl J Med* 2004;351:2817-26.
26. Jansen MP, Foekens JA, van Staveren IL, et al. Molecular classification of tamoxifen-resistant breast carcinomas by gene expression profiling. *J Clin Oncol* 2005;23:732-40.
27. Hess KR, Anderson K, Symmans WF, et al. Pharmacogenomic predictor of sensitivity to preoperative chemotherapy with paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide in breast cancer. *J Clin Oncol* 2006;24:4236-44.
28. Bueno-de-Mesquita JM, van Harten WH, Retel VP, et al. Use of 70-gene signature to predict prognosis of patients with node-negative breast cancer: a prospective community-based feasibility study (RASTER). *Lancet Oncol* 2007;8:1079-87.
29. van de Vijver MJ, Mooi WJ, Wisman P, Peterse JL, Nusse R. Immunohistochemical detection of the neu protein in tissue sections of human breast tumors with amplified neu DNA. *Oncogene* 1988;2:175-8.
30. Balaton AL, Coindre JM, Collin F, et al. Recommendations for the immunohistochemical evaluation of hormone receptors on paraffin sections of breast cancer. Study Group on Hormone Receptors using Immunohistochemistry FNCLCC/AFAQAP. National Federation of Centres to Combat Cancer/French Association for Quality Assurance in Pathology. *Ann Pathol* 1996;16:144-8.
31. Glas AM, Floore A, Delahaye LJ, et al. Converting a breast cancer microarray signature into a high-throughput diagnostic test. *BMC Genomics* 2006;7:278.
32. Weng L, Dai H, Zhan Y, He Y, Stepaniants SB, Bassett DE. Rosetta error model for gene expression analysis. *Bioinformatics* 2006;22:1111-21.
33. Cohen J. A coefficient of agreement for nominal scales. *Educ Psychol Meas* 1960;20:37-46.
34. Bast RC, Jr., Ravdin P, Hayes DF, et al. 2000 update of recommendations for the use of tumor markers in breast and colorectal cancer: clinical practice guidelines of the American Society of Clinical Oncology. *J Clin Oncol* 2001;19:1865-78.
35. Gong Y, Yan K, Lin F, et al. Determination of oestrogen-receptor status and ERBB2 status of breast carcinoma: a gene-expression profiling study. *Lancet Oncol* 2007;8:203-11.
36. Badve SS, Baehner FL, Gray RP, et al. Estrogen- and progesterone-receptor status in ECOG 2197: comparison of immunohistochemistry by local and central laboratories and quantitative reverse transcription polymerase chain reaction by central laboratory. *J Clin Oncol* 2008;26:2473-81.
37. Goldhirsch A, Glick JH, Gelber RD, Coates AS, Thürlimann B, Senn HJ. Meeting highlights: international expert consensus on the primary therapy of early breast cancer 2005. *Ann Oncol* 2005;16:1569-83.
38. Schnitt SJ. Estrogen receptor testing of breast cancer in current clinical practice: what's the question? *J Clin Oncol* 2006;24:1797-9.
39. van Dijk MA, Floore AN, Kloppenborg KI, van't Veer LJ. A functional assay in yeast for the human estrogen receptor displays wild-type and variant estrogen receptor messenger RNAs present in breast carcinoma. *Cancer Res* 1997;57:3478-85.
40. van't Veer LJ, Dai H, van de Vijver MJ, et al. Gene expression profiling predicts clinical outcome of breast cancer. *Nature* 2002;415:530-6.
41. Creighton CJ, Kent Osborne C, van de Vijver MJ, et al. Molecular profiles of progesterone receptor loss in human breast tumors. *Breast Cancer Res Treat* 2009;114:287-99.
42. Vogel CL, Cobleigh MA, Tripathy D, et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. *J Clin Oncol* 2002;20:719-26.

# Clinical Cancer Research

## Microarray-Based Determination of Estrogen Receptor, Progesterone Receptor, and HER2 Receptor Status in Breast Cancer

Paul Roepman, Hugo M. Horlings, Oscar Krijgsman, et al.

*Clin Cancer Res* 2009;15:7003-7011. Published OnlineFirst November 3, 2009.

**Updated version** Access the most recent version of this article at:  
doi:[10.1158/1078-0432.CCR-09-0449](https://doi.org/10.1158/1078-0432.CCR-09-0449)

**Cited articles** This article cites 42 articles, 20 of which you can access for free at:  
<http://clincancerres.aacrjournals.org/content/15/22/7003.full#ref-list-1>

**Citing articles** This article has been cited by 9 HighWire-hosted articles. Access the articles at:  
<http://clincancerres.aacrjournals.org/content/15/22/7003.full#related-urls>

**E-mail alerts** [Sign up to receive free email-alerts](#) related to this article or journal.

**Reprints and Subscriptions** To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at [pubs@aacr.org](mailto:pubs@aacr.org).

**Permissions** To request permission to re-use all or part of this article, use this link  
<http://clincancerres.aacrjournals.org/content/15/22/7003>.  
Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.